Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Clinical and microbiological characteristics of Rhodotorula mucilaginosa infections in a tertiary-care facility.

Capoor MR, Aggarwal S, Raghvan C, Gupta DK, Jain AK, Chaudhary R.

Indian J Med Microbiol. 2014 Jul-Sep;32(3):304-9. doi: 10.4103/0255-0857.136576.

2.

Molecular identification, antifungal susceptibility profile, and biofilm formation of clinical and environmental Rhodotorula species isolates.

Nunes JM, Bizerra FC, Ferreira RC, Colombo AL.

Antimicrob Agents Chemother. 2013 Jan;57(1):382-9. doi: 10.1128/AAC.01647-12. Epub 2012 Oct 31.

3.

Rhodotorula spp. isolated from blood cultures: clinical and microbiological aspects.

De Almeida GM, Costa SF, Melhem M, Motta AL, Szeszs MW, Miyashita F, Pierrotti LC, Rossi F, Burattini MN.

Med Mycol. 2008 Sep;46(6):547-56. doi: 10.1080/13693780801972490.

PMID:
19180725
4.

Central venous catheter-associated fungemia due to Rhodotorula spp. --a systematic review.

Tuon FF, de Almeida GM, Costa SF.

Med Mycol. 2007 Aug;45(5):441-7. Review.

PMID:
17654271
5.

Rhodotorula fungemia of an intensive care unit patient and review of published cases.

Spiliopoulou A, Anastassiou ED, Christofidou M.

Mycopathologia. 2012 Oct;174(4):301-9. doi: 10.1007/s11046-012-9552-9. Epub 2012 May 11. Review.

PMID:
22576941
6.

Rhodotorula fungemia: two cases and a brief review.

Duggal S, Jain H, Tyagi A, Sharma A, Chugh TD.

Med Mycol. 2011 Nov;49(8):879-82. doi: 10.3109/13693786.2011.583694. Epub 2011 May 19. Review.

PMID:
21595509
7.

Five-year evaluation of bloodstream yeast infections in a tertiary hospital: the predominance of non-C. albicans Candida species.

Pereira GH, Müller PR, Szeszs MW, Levin AS, Melhem MS.

Med Mycol. 2010 Sep;48(6):839-42. doi: 10.3109/13693780903580121.

PMID:
20163281
8.

In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.

Trpković A, Pekmezović M, Barać A, Crnčević Radović L, Arsić Arsenijević V.

J Mycol Med. 2012 Sep;22(3):243-8. doi: 10.1016/j.mycmed.2012.06.002. Epub 2012 Aug 10.

PMID:
23518082
9.

Drug susceptibility of 64 strains of Rhodotorula sp.

Krzyściak P, Macura AB.

Wiad Parazytol. 2010;56(2):167-70.

PMID:
20707302
10.

Epidemiology and outcome of Rhodotorula fungemia in a tertiary care hospital.

Lunardi LW, Aquino VR, Zimerman RA, Goldani LZ.

Clin Infect Dis. 2006 Sep 15;43(6):e60-3. Epub 2006 Aug 8.

PMID:
16912936
11.

[Fungemia caused by Rhodotorula mucilaginosa in relation to total parenteral nutrition].

Jiménez-Mejías ME, Ortiz Leyba C, Jiménez Gonzalo FJ, del Nozal M, Campos T, Jiménez Jiménez FJ.

Enferm Infecc Microbiol Clin. 1992 Nov;10(9):543-6. Spanish.

PMID:
1489796
12.

Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review.

Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M.

J Antimicrob Chemother. 2005 Mar;55(3):312-6. Epub 2005 Feb 4.

PMID:
15695538
13.

Rhodotorula mucilaginosa Fungemia and Pleural Tuberculosis in an Immunocompetent Patient: An Uncommon Association.

Pereira C, Ribeiro S, Lopes V, Mendonça T.

Mycopathologia. 2016 Feb;181(1-2):145-9. doi: 10.1007/s11046-015-9942-x. Epub 2015 Sep 14.

PMID:
26369644
14.

Fungemia due to Rhodotorula mucilaginosa in an immunocompetent, critically ill patient.

Monterrubio Villar J, González Velasco C, Jiménez Delgado JD.

Kansenshogaku Zasshi. 2013 Sep;87(5 Suppl 8):10-2.

PMID:
24475695
15.

Fungemia due to Rhodotorula mucilaginosa after allogeneic hematopoietic stem cell transplantation.

Mori T, Nakamura Y, Kato J, Sugita K, Murata M, Kamei K, Okamoto S.

Transpl Infect Dis. 2012 Feb;14(1):91-4. doi: 10.1111/j.1399-3062.2011.00647.x. Epub 2011 Apr 28. Review.

PMID:
21535337
16.

Rhodotorula mucilaginosa catheter-related fungaemia in a patient with multiple myeloma.

García-Suárez J, Gómez-Herruz P, Cuadros JA, Guillén H, Burgaleta C.

Mycoses. 2011 Jul;54(4):e214-6. doi: 10.1111/j.1439-0507.2009.01816.x. Epub 2009 Dec 23.

PMID:
20041994
17.

Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates.

Zaas AK, Boyce M, Schell W, Lodge BA, Miller JL, Perfect JR.

J Clin Microbiol. 2003 Nov;41(11):5233-5.

18.

Identification, antifungal susceptibility and scanning electron microscopy of a keratinolytic strain of Rhodotorula mucilaginosa: a primary causative agent of onychomycosis.

da Cunha MM, dos Santos LP, Dornelas-Ribeiro M, Vermelho AB, Rozental S.

FEMS Immunol Med Microbiol. 2009 Apr;55(3):396-403. doi: 10.1111/j.1574-695X.2009.00534.x. Epub 2009 Jan 26.

19.

Rhodotorula minuta as onychomycosis agent in a Chinese patient: first report and literature review.

Zhou J, Chen M, Chen H, Pan W, Liao W.

Mycoses. 2014 Mar;57(3):191-5. doi: 10.1111/myc.12143. Epub 2013 Oct 11. Review.

PMID:
24118107
20.

Isolation of Rhodotorula mucilaginosa from blood cultures in a tertiary care hospital.

Falces-Romero I, Cendejas-Bueno E, Romero-Gómez MP, García-Rodríguez J.

Mycoses. 2018 Jan;61(1):35-39. doi: 10.1111/myc.12703. Epub 2017 Oct 13.

PMID:
28922488

Supplemental Content

Support Center